PositiveID’s President to Present “Mobile Labs: Bringing Labs to the Point of Need” and Chief Scientist to speak on “Disruptive Innovation in Laboratory Medicine: Game-Changing Technologies and Approaches” panel
DELRAY BEACH, Fla., Aug. 18, 2016 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that it will present and exhibit as a premier sponsor at the Next Generation Dx Summit from August 23-26, 2016, at the Grand Hyatt Washington in Washington, D.C. PositiveID’s President, Lyle L. Probst, will feature the Company’s E-N-G Mobile Systems subsidiary, a leader in mobile laboratories, in his presentation: “Mobile Labs: Bringing Labs to the Point of Need.”
PositiveID’s Chief Scientist, Dr. Kimothy Smith, will be a panel speaker during the “Disruptive Innovation in Laboratory Medicine: Game-Changing Technologies and Approaches” session. The Company will also exhibit its mobile labs, molecular diagnostics and medical device businesses.
PositiveID’s E-N-G Mobile Systems (“ENG”) business is a leader in engineering and producing its proprietary MobiLab™ Systems, mobile labs for biological, chemical, radiological and nuclear testing applications. Over 400 ENG MobiLabs are in operation throughout the world. ENG was the first company to install gas chromatography in a mobile lab, and is a pioneer in developing mobile platforms that allow standard laboratory-grade instruments to be operated successfully in the field.
During the plenary session, Smith will feature PositiveID’s Firefly Dx, a point-of-need (“PON”), handheld system designed to deliver molecular diagnostic results from a sample in less than 30 minutes, compared to hours or even days for a lab device, using real-time PCR (polymerase chain reaction) chemistry. Firefly’s applications include PON, lab-quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.
The Next Generation Dx Summit convenes more than 1,000 international diagnostic professionals for valuable networking and comprehensive programming spanning from clinical diagnostics to business strategy. Now in its eighth year, the event has grown to include novel immunotherapy biomarkers, cell-free DNA, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, commercialization, and reimbursement.
About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.
Statements about PositiveID’s future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID’s actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the professional healthcare and laboratory markets, as well as other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on April 12, 2016, and 10-Qs filed on August 12, May 16, 2016, and November 12, 2015, under the caption “Risk Factors.” The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.